Thermo Fisher Scientific Baltics: Strategic Biotech Supply Chains and Bio-Surveillance
Strategic analysis of Thermo Fisher Scientific Baltics: Molecular biology reagents and diagnostic hardware securing European bio-surveillance supply chains
13 pages · PDF · 26 December 2025 · Licensed single-user copy, watermarked to the buyer
Tactical Biotechnology, Human Enhancement & MedTech Lithuania
€299 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
Thermo Fisher Scientific Baltics, UAB is a Lithuanian-based manufacturing subsidiary of global life-sciences giant Thermo Fisher Scientific. Established on the former site of the Fermentas biotech spin‑off, its Vilnius facility is a cornerstone of Europe’s biotechnology supply chain .
The company specializes in the development and production of molecular biology and analytical chemistry products – reagents, enzymes, master mixes and laboratory instruments – that serve research, diagnostics and industrial customers worldwide . With over 1,400 employees at its Lithuanian headquarters , Thermo Fisher Baltics contributes roughly 2–3% of Lithuania’s GDP , reflecting its scale.
Key questions this report answers
- What is Thermo Fisher Baltics' core production of molecular biology and analytical chemistry products (reagents, enzymes, master mixes, instruments)?
- How does its Vilnius facility, built on the former Fermentas site, anchor Europe's biotechnology supply chain and bio-surveillance?
- What does its scale (over 1,400 employees and roughly 2-3% of Lithuania's GDP) imply for strategic dependencies?
- What capability gaps and dual-use potential define its strategic significance?
Who it's for
Investors screening Thermo Fisher Scientific Baltics, UAB, competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (26 December 2025). You receive a 13-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Tactical reports · Biotechnology, Human Enhancement & MedTech · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →